PDCD1 and rectal cancer: A recent Phase II study of neoadjuvant PD-1 blockade (dostarlumab) in locally advanced rectal cancer showed 100% complete clinical responses in all 12 patients, with no one having surgery or a relapse, with a median follow-up duration of 12 months [36].